Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284478 · ClinicalTrials.gov registry record · Phase 2
Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery
A Phase 2 study, sponsored by Northern California Retina Vitreous Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01284478: Completed Phase 2 study, sponsored by Northern California Retina Vitreous Associates.
NCT01284478 is a Phase 2 study that has completed, run by Northern California Retina Vitreous Associates. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01284478, a Phase 2 study, has completed, sponsored by Northern California Retina Vitreous Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery
Interventions
- DRUG Dexamethasone Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT01284478 record still lists
NCT01284478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone Implant is the first listed.
NCT01284478 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01284478 about?
NCT01284478 is a clinical study titled "Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery". The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery
What is the current status of trial NCT01284478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2011-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01284478?
The interventions under investigation include: Dexamethasone Implant (DRUG).
Who is sponsoring clinical trial NCT01284478?
This trial is sponsored by Northern California Retina Vitreous Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01284478's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia